Petrelintide
An experimental long-acting human amylin analog from Zealand Pharma and Roche, taken weekly.
- Evidence
- Ongoing clinical research
- Half-life
- Days
- Sources
- 2 cited
Is petrelintide FDA-approved?
Investigational. Not FDA-approved.
Overview
Petrelintide is built to feel more like natural amylin, with the hope of fewer stomach side effects than GLP-1 medicines. In the 28-week ZUPREME 1 phase 2 trial, people with obesity lost about 8–10% of body weight on average depending on dose.
How it works
It acts on amylin and calcitonin receptors in the brain to increase fullness and slow the stomach.
How long does petrelintide stay in the body?
Long enough for once-weekly shots in trials.
What it's studied for
- Obesity
- Combination with GLP-1 medicines
Reported side effects
- Nausea and other stomach side effects, mostly mild
Related: Maridebart Cafraglutide, Eloralintide, Amycretin, Pemvidutide.
Sources
The studies and prescribing labels this page is written from.
- Petrelintide for the treatment of obesity (ZUPREME 1): a phase 2 trial. Lancet Diabetes Endocrinol, 2026 PubMed
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem, 2025 PubMed
